Asthma. Predominantly allergic asthma
Conditions
Interventions
1000 mg Omega-3fish oil (Best Formulations Inc., LA, CA, USA) in the form of softgel capsules including 180 mg EPA (icosapentaenoic acid) and 120 mg DHA (docosahexaenoic acid) daily for consecutive th
Treatment - Drugs
Sponsors
Vice-Chancellery of Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
4 Years to 16 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: children with asthma diagnosed by sub specialist of asthma and allergy Exclusion criteria: history of allergy to seafood; those under treatment with anti- leukotrienes and aspirin; side effects such as nausea and vomiting
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory symptoms including cough and wheeze. Timepoint: pre intervention and 3 months after intervention. Method of measurement: Questionnarie based on cough and wheeze in day and night. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function. Timepoint: before intervention and after 3 months intervention. Method of measurement: spirometry.;Inflammatory and anti inflammatory cytokines. Timepoint: pre intervention and 3 months after intervention. Method of measurement: using flowcytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMozhgan Moghtaderi
Allergy Research Center, Shiraz University of Medical Sciences
Outcome results
None listed